Ironwood Pharmaceuticals (IRWD) Research Coverage Started at Credit Suisse Group
Credit Suisse Group initiated coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) in a research note released on Monday. The firm issued a buy rating and a $19.00 price target on the biotechnology company’s stock.
Several other equities analysts have also recently issued reports on the stock. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 25th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 1st. Mizuho restated a buy rating and set a $23.00 target price (up previously from $22.00) on shares of Ironwood Pharmaceuticals in a research note on Wednesday, August 2nd. Finally, Cowen set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $18.38.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $17.13 on Monday. Ironwood Pharmaceuticals has a one year low of $13.43 and a one year high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. The company had revenue of $86.80 million for the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. Ironwood Pharmaceuticals’s revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.18) EPS. sell-side analysts forecast that Ironwood Pharmaceuticals will post -1.12 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of IRWD. Teachers Advisors LLC lifted its stake in Ironwood Pharmaceuticals by 2.5% during the 1st quarter. Teachers Advisors LLC now owns 231,163 shares of the biotechnology company’s stock valued at $3,944,000 after acquiring an additional 5,567 shares during the period. Renaissance Technologies LLC bought a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $3,181,000. KCG Holdings Inc. lifted its stake in shares of Ironwood Pharmaceuticals by 20.5% in the 1st quarter. KCG Holdings Inc. now owns 14,270 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 2,428 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $652,000. Finally, Aperio Group LLC lifted its stake in shares of Ironwood Pharmaceuticals by 11.9% in the 2nd quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the period.
ILLEGAL ACTIVITY NOTICE: “Ironwood Pharmaceuticals (IRWD) Research Coverage Started at Credit Suisse Group” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/11/30/ironwood-pharmaceuticals-irwd-research-coverage-started-at-credit-suisse-group.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.